Bone Biologics Corporation (BBLG) Cash Flow Statement
Where BBLG’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$2.7M
- Capital expenditures
- $0
- Free cash flow
- −$2.7M
- Returned to shareholders
- —
- Change in cash
- $2.0M cash at year-end $5.3M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BBLG operating cash flow, capex and free cash flow
BBLG cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$7.3M2016 | −$2.7M2025 | — | |
| Capital expenditures | $02016 | $02025 | — | |
| Free cash flow | −$7.3M2016 | −$2.7M2025 | — | |
| Stock-based compensation | $3.5M2016 | $256,3582025 | −25.1%/yr | |
| Dividends paid | $02016 | $3.2M2024 | — | |
| Share buybacks (net) | $02016 | $02018 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BBLG cash flow by activity
BBLG net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BBLG cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$3.1M | −$4.1M | −$8.9M | −$1.5M | −$1.6M | −$1.8M | −$3.4M | −$4.4M | −$7.1M | −$21.0M |
| Depreciation & amortization | — | $4.2M | $9.4M | — | — | $0 | $50 | $96 | $96 | $700 |
| Stock-based compensation | $256,358 | $188,819 | $152,599 | $266,633 | $207,035 | $60,000 | $49,692 | $516,638 | −$584,027 | $3.5M |
| Change in working capital | $165,450 | −$150,253 | $132,921 | −$168,373 | −$320,487 | $399,682 | $143,782 | $145,539 | $938,742 | $144,478 |
| Other non-cash items | −$3,967 | −$4.3M | −$10.3M | −$2.2M | $495,551 | $938,075 | −$19,942 | −$336,758 | $3.4M | $10.1M |
| Cash from operating activities | −$2.7M | −$4.1M | −$9.6M | −$3.6M | −$1.2M | −$426,933 | −$3.3M | −$4.1M | −$3.3M | −$7.3M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$5 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Cash from investing activities | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Financing activities | ||||||||||
| Dividends paid | — | −$3.2M | — | — | — | — | — | $0 | $0 | $0 |
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | $0 | $557,991 | $2.8M |
| Net borrowing (repayment) | — | — | — | $0 | $1.0M | $402,788 | $2.3M | $2.3M | $2.7M | $3.1M |
| Shares issued | $4.7M | $2.6M | $8.9M | $4.4M | $6.9M | $0 | $0 | $4.4M | $0 | $0 |
| Other financing | $0 | $5.0M | −$3.8M | $0 | $0 | $0 | $0 | −$2.3M | $142,009 | $959,406 |
| Cash from financing activities | $4.7M | $4.4M | $5.0M | $4.4M | $7.9M | $402,788 | $2.3M | $4.4M | $3.4M | $6.8M |
| Summary | ||||||||||
| Net change in cash | $2.0M | $298,562 | −$4.5M | $862,947 | $6.7M | −$24,145 | −$931,229 | $265,095 | $69,904 | −$494,734 |
| Cash at end of period | $5.3M | $3.3M | $3.0M | $7.5M | $6.7M | $2,461 | $24,145 | $955,374 | $690,279 | $620,375 |
| Free cash flow | −$2.7M | −$4.1M | −$9.6M | −$3.6M | −$1.2M | −$426,933 | −$3.3M | −$4.1M | −$3.3M | −$7.3M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$773,702 | −$765,988 | −$684,643 | −$666,737 | −$740,519 | −$1.0M | −$1.5M | −$941,000 | −$783,733 | −$865,970 | −$1.5M | −$1.9M |
| Depreciation & amortization | — | — | — | $715,274 | — | — | — | — | — | — | $1.2M | $2.1M |
| Stock-based compensation | $8,253 | $23,505 | $45,674 | $87,180 | $72,899 | $50,605 | $100,754 | $17,941 | $17,443 | $52,681 | $71,139 | $20,026 |
| Change in working capital | $246,901 | −$61,534 | −$75,295 | −$10,615 | $209,643 | $41,717 | $80,423 | $340,925 | −$118,790 | −$452,811 | −$514,506 | −$494,894 |
| Other non-cash items | $108 | −$265 | −$498 | −$716,486 | −$902 | −$1,355 | −$12,959 | $9,972 | −$10,785 | −$37,311 | −$1.2M | −$2.2M |
| Cash from operating activities | −$518,440 | −$804,282 | −$714,762 | −$591,384 | −$458,879 | −$926,125 | −$1.4M | −$572,162 | −$895,865 | −$1.3M | −$2.0M | −$2.6M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | −$5 | $0 | −$5 | −$5 | −$3 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | ||||||||||||
| Dividends paid | — | — | — | — | — | — | −$3.2M | −$3.2M | — | — | — | — |
| Shares issued | $20,180 | $0 | $0 | $0 | $4.4M | $347,549 | $1.1M | $0 | $0 | $1.5M | $591,998 | $0 |
| Other financing | $0 | $0 | $0 | $0 | $0 | $0 | $3.2M | $5.0M | $299 | $0 | $0 | $4.4M |
| Cash from financing activities | $20,180 | $0 | $0 | $0 | $4.4M | $347,549 | $1.1M | $1.8M | $299 | $1.5M | $591,998 | $4.4M |
| Summary | ||||||||||||
| Net change in cash | −$498,260 | −$804,282 | −$714,762 | −$591,384 | $3.9M | −$578,576 | −$241,295 | $1.2M | −$895,566 | $201,065 | −$1.4M | −$2.6M |
| Cash at end of period | $4.0M | $4.5M | $5.3M | $6.0M | $6.6M | $2.7M | $3.3M | $3.6M | $2.3M | $3.2M | $3.0M | $4.5M |
| Free cash flow | −$518,440 | −$804,280 | −$714,762 | −$591,384 | −$458,879 | −$926,120 | −$1.4M | −$572,162 | −$895,865 | −$1.3M | −$2.0M | −$2.6M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BBLG cash generation
In fiscal 2025 (ended December 31, 2025), Bone Biologics generated -$2.7 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$2.7 million. Cash and equivalents rose by $2.0 million over the year.
Related: BBLG income statement, BBLG balance sheet. See the BBLG stock overview for the latest quote and news.
BBLG cash flow FAQ
What is Bone Biologics's free cash flow?
Bone Biologics's free cash flow was -$2.7 million in fiscal 2025: -$2.7 million of operating cash flow minus $0 of capital expenditures It was -$4.1 million a year earlier..
How much cash does Bone Biologics generate from operations?
Bone Biologics generated -$2.7 million of cash from operating activities in fiscal 2025.